Indegene deployed a powerful predictive analytics model to enable early diagnosis of invasive Group B Streptococcus (GBS) for a leading global biopharmaceutical company developing safe, effective medicines and vaccines. The software analyzed patient vitals and lab values—like aspartate aminotransferase and albumin—as key predictors, identifying invasive patterns before symptoms emerged. This proactive approach transformed real-world data into actionable insights, pinpointing at-risk adults with bacterial infections, accelerating timely interventions, reducing disease progression, and enhancing patient outcomes through precise, data-driven decision-making.

Join for free to read